1400 Seaport Blvd, Building B
48 articles about HeartFlow
TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights
HeartFlow, Inc., a leader in non-invasive integrated artificial intelligence heart care solutions, announced results from three clinical studies supporting the use of advanced coronary computed tomography angiography -based technologies in the assessment of patients with suspected coronary artery disease.
HeartFlow, Inc. to Announce New Data on Diagnosing and Managing Coronary Artery Disease at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting
HeartFlow, Inc., the only non-invasive precision coronary care solution to provide both anatomic and physiologic insights, today announced that new data on HeartFlow Plaque Analysis and its RoadMapTM Analysis will be presented at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Boston, MA.
New HeartFlow RoadMap™ Analysis Now Available in U.S. to Assist CT Readers in Identifying Coronary Artery Narrowings
HeartFlow, Inc. announced the launch of the RoadMap analysis, a new AI-enabled product that assists CT readers to accurately*, efficiently, and consistently identify stenoses in the coronary arteries.
HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences
HeartFlow, Inc. announced the close of a $215 million Series F funding round by its parent company HeartFlow Holding, Inc., led by Bain Capital Life Sciences with participation from new investor Janus Henderson Investors, and existing investors including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management.
HeartFlow Announces Late Breakers Presentation at the 2022 American Heart Association (AHA) Scientific Sessions
HeartFlow, Inc., the leader in revolutionizing precision heart care, announced that the results of the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization will be presented as Late Breaking Science at the upcoming annual American Heart Association conference, held November 5-7 virtually and in Chicago, Illinois.
Presented at SCCT - New Plaque Clinical Data Provides Additional Insights on Anatomy and Physiology in Clinical Decision Making for Patients
HeartFlow, Inc., the leader in revolutionizing precision heart care, released two datasets utilizing its HeartFlow AI-based Plaque technology* (referred in below as “HeartFlow Plaque”).
3/4/2022Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
HeartFlow Holding, Inc. today announced that it and Longview Acquisition Corporation II (NYSE: LGV), a special purpose acquisition company sponsored by affiliates of Glenview Capital Management, LLC, have mutually agreed to terminate their previously announced business combination agreement, effective immediately, as a result of current unfavorable market conditions.
HeartFlow Holding, Inc., the leader in revolutionizing precision heart care, announced the appointment of Timothy Barabe to its Board of Directors.
HeartFlow, Inc., the leader in revolutionizing precision heart care, announced the appointment of Wayne J. Riley, MD, to its Board of Directors.
HeartFlow Holding, Inc ., the leader in revolutionizing precision heart care, today announced the company will be participating in two upcoming virtual investor conferences.
HeartFlow Analysis is First AI-Enabled Technology to be Recognized by the American College of Cardiology and American Heart Association Guidelines as an Important Tool in Diagnosing and Treating Heart Disease
HeartFlow, Inc. welcomed new clinical practice guidelines from the American College of Cardiology and American Heart Association that recognized the HeartFlow FFRct Analysis with Class of Recommendation 2a, identifying it as an important tool for diagnosing coronary artery disease and guiding decision-making regarding the use of revascularization procedures such as coronary stenting or bypass surgery.
HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE TrialTrial to evaluate new technology that may help physicians prevent heart attacks in patients
HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to AnaLyze PLAQUE using CCTA) trial to evaluate HeartFlow’s non-invasive plaque technology, an automated, deep learning-based method for identifying, characterizing and segmenting plaque in the coronary arteries.
HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference.
8/6/2021Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.
Medtech company HeartFlow is heading to the New York Stock Exchange through a merger with special purpose acquisition company, Longview Acquisition Corp. II.
HeartFlow, the Leader in Precision Heart Care, Announces Merger with Longview Acquisition Corp. II to Become a Publicly Traded Company
HeartFlow announced today that they have entered into a definitive business combination agreement that will support HeartFlow’s vision of revolutionizing precision heart care.
HeartFlow, Inc., a leader in revolutionizing precision heartcare, announced new data demonstrating the accuracy of the HeartFlow Planner in providing modeled post-percutaneous coronary intervention fractional flow reserve derived from computed tomography values, which are an important measure for understanding the effectiveness of a PCI procedure, such as a stent implantation.
New 10-Year Data Demonstrate Superiority of the HeartFlow Analysis in Predicting Long-Term Outcomes in Patients With Coronary Artery Disease
HeartFlow, Inc., a leader in revolutionizing precision heartcare, announced new data which indicate that the information provided by the HeartFlow FFRct Analysis was a superior predictor of 10-year outcomes compared to the severity of a coronary stenosis shown on a coronary computed tomography angiogram.
HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced the completion of patient enrollment in the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) randomized controlled trial. Physicians from more than 50 hospitals around the world successfully enrolled 2,100 patients.